Quantcast

Latest Upsher-Smith Laboratories Inc. Stories

2014-07-14 08:27:51

Authorized Generic Topiramate Extended-Release Capsules Available Nationwide MAPLE GROVE, Minn., July 14, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the launch of Topiramate Extended-Release Capsules, the authorized generic of the recently Food and Drug Administration (FDA) approved Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK)...

2014-07-02 08:27:35

Testosterone Gel (1%), the Generic Equivalent to Vogelxo(TM) (testosterone) Gel, Expected to Increase Access for Patients Who Need It MAPLE GROVE, Minn., July 2, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced the launch of Testosterone Gel (1%), the generic of the newly Food and Drug Administration (FDA) approved Vogelxo((TM)) (testosterone) gel 1%, for topical use, CIII, and the first and only available generic testosterone replacement therapy (TRT) available in three...

2014-06-30 08:31:21

First Branded Product in CNS Portfolio Now Available MAPLE GROVE, Minn., June 30, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that Qudexy(TM) XR (topiramate) extended-release capsules is now available to patients in the United States. Qudexy(TM) XR is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. It was approved by the U.S. Food and Drug Administration in March 2014...

2014-06-17 08:26:35

Recently FDA Approved Qudexy(TM) XR Offers a New Treatment Option for Managing Specific Seizure Types MAPLE GROVE, Minn., June 17, 2014 /PRNewswire/ -- Results from Upsher-Smith Laboratories, Inc.'s, Phase 3 study of USL255, Qudexy(TM) XR (topiramate) extended-release capsules, a proprietary, once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile, were published in the June issue of Epilepsia, a leading, authoritative...

2014-06-09 16:25:52

MAPLE GROVE, Minn., June 9, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced that it is the recipient of a Distribution Industry Award for Notable Achievements in Healthcare (DIANA) given by the Healthcare Distribution Management Association (HDMA). The Company was presented with one of the two "2014 DIANA Manufacturer Partner of the Year" awards. The Company was also recognized as a Merit Finalist for the "Best Overall Branded Pharmaceutical Product Manufacturer...

2014-06-04 16:25:56

MAPLE GROVE, Minn., June 4, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo(TM) (testosterone) gel for topical use CIII. The company is preparing to launch Vogelxo(TM) in the near future. http://photos.prnewswire.com/prnvar/20130520/NY17281LOGO About Upsher-SmithUpsher-Smith Laboratories, Inc., founded in 1919, is a growing...

2014-04-29 16:31:05

USL261 Demonstrates Promising PK, PD and Safety Profiles in Patients with Epilepsy PHILADELPHIA, April 29, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that Phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66(th)( )Annual American Academy of Neurology (AAN) meeting in Philadelphia. The results demonstrated that USL261 at a single dose of up to 7.5 mg was rapidly absorbed and exhibited a...

2014-04-21 12:27:11

Upsher-Smith-sponsored data to include the first presentation of pooled Phase 1 data on the adverse event profile of USL255 (Qudexy(TM) XR (topiramate) extended-release capsules) MAPLE GROVE, Minn., April 21, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), will highlight new pooled phase 1 data from studies in healthy adults comparing the adverse event profile of USL255 (Qudexy(TM) XR) with immediate-release topiramate in a poster presentation at the 66(th) Annual Meeting...

2014-03-24 16:24:14

MAPLE GROVE, Minn., March 24, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), today announced that it has entered into a definitive agreement under which New Jersey-based Vertical Pharmaceuticals, LLC has acquired Upsher-Smith's rights to Divigel(®) (estradiol gel) 0.1%, Nexa(®) Plus Rx Prenatal Vitamin, and Provella(®), a...

2014-03-12 12:29:03

Qudexy(TM) XR Offers Newest Option for Managing Certain Seizure Disorders and Marks the Company's Entrance into the Epilepsy Therapeutic Area MAPLE GROVE, Minn., March 12, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced it received approval on March 11, 2014 from the U.S. Food and Drug Administration (FDA) for Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related